Categories: NewsSports medicine

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com 

Staff

Recent Posts

AIxMed and CorePlus Partner to Demonstrate a Digital Urine Cytology Workflow Solution

AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics.…

4 hours ago

Custom Health Enters into Definitive Agreement to Complete Business Combination with Queue Ventures

Vancouver, British Columbia--(Newsfile Corp. - May 30, 2025) - Custom Health, Inc. ("Custom Health"), a…

10 hours ago

Vaniam Group™ Introduces Vaniam Intelligence™: Purpose-Built AI, Guided by Human Insight

CHICAGO, Ill., May 30, 2025 /PRNewswire/ -- Vaniam Group™, a leader in medical communications, is…

10 hours ago

Provider Network Holdings Appoints Dr. Edith A. Perez, M.D. as Chief Medical Officer of Cornerstone Specialty Network

PEARLAND, Texas, May 30, 2025 /PRNewswire/ -- Cornerstone Specialty Network ("Cornerstone"), a leading provider of…

10 hours ago

California Students Recognized for Designing Digital Interventions in Support of Teen Mental Health and Wellness

Youth-led solutions support healthier tech use and peer wellness SACRAMENTO, Calif., May 30, 2025 /PRNewswire/…

10 hours ago

Supply Chain Leadership Acknowledged for Paving the Way for MedTech Innovation and Growth

Sanjay Gupta from Imbed Biosciences Inc. Featured in The Wall Street Journal as a Distinguished…

10 hours ago